3T Biosciences

Focus: 3T Biosciences is a public biotech company founded in 2017 specializing in TCR (T-cell receptor) therapies for immunology and neurology indications. The company is early-stage with minimal commercial infrastructure and a highly focused pipeline.

Immunology Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About 3T Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow 3T Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Dynamic Light Scattering Ocular Measurement in the Detection of Dementia

Dementia

N/A

Clinical Trials (1)

NCT06613971Dynamic Light Scattering Ocular Measurement in the Detection of Dementia

N/A

Help build intelligence for 3T Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build clinical operations from the ground up—recent appointment of Head of Clinical Operations (March 2026) signals expansion phase
Specialized TCR modality offers deep technical expertise in an emerging immunotherapy area with significant patent protection potential
Public company status provides equity upside and visibility, versus pre-revenue risk of earlier-stage peers

Watch Out For

Only 2 active job openings suggest minimal hiring; limited career momentum and team expansion
Pipeline is underdeveloped with no Phase 1-3 trials active and sole program in early detection (not drug development), indicating execution risk or strategic pivot
Undisclosed financials, employee count, and funding raise questions about capital adequacy and runway sustainability

Generated by Claude from 3T Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.